Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.60 +1.15 (+2.72%)
Streaming Delayed Price Updated: 1:06 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Outlook For Veracyte ↗
 
Via Benzinga
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes Acquisition of C2i Genomics
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Veracyte ↗
 
Via Benzinga
News headline image
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares ↗
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO). 
Via Benzinga
Topics ETFs
News headline image
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
From Veracyte, Inc.
Via Business Wire
News headline image
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
News headline image
Veracyte Announces Third Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 7, 2023 ↗
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Veracyte to Participate in the Stephens Annual Investment Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
From Veracyte, Inc.
Via Business Wire
News headline image
7 Undervalued Stocks That Analysts Love Right Now ↗
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. 
Via InvestorPlace
News headline image
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Stock Is Volatile After-Hours - Here's Why ↗
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier... 
Via Benzinga
News headline image
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
From Veracyte, Inc.
Via Business Wire
News headline image
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? ↗
The genetic test maker is rapidly increasing test volumes. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.